Biogen Inc said on Friday it would discontinue the development of its experimental therapy for a rare brain disease after the treatment failed a mid-stage trial, the latest setback in attempts to develop a therapy for the disorder.
Biogen Inc said on Friday it would discontinue the development of its experimental therapy for a rare brain disease after the treatment failed a mid-stage trial, the latest setback in attempts to develop a therapy for the disorder.